Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068482302> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2068482302 endingPage "511" @default.
- W2068482302 startingPage "507" @default.
- W2068482302 abstract "In recent years, antibody therapy has become a new treatment modality for tumour patients, although the majority of responses are only partial and not long lasting. Based on evidence that effector-cell-mediated mechanisms significantly contribute to antibody efficacy in vivo, several approaches are currently pursued to improve the interaction between Fc receptor-expressing effector cells and tumour target antigens. These approaches include application of Fc receptor-directed bispecific antibodies, which contain one specificity for a tumour-related antigen and another for a cytotoxic Fc receptor on immune effector cells. Thereby, bispecific antibodies selectively engage cytotoxic trigger molecules on killer cells, avoiding, for example, interaction with inhibitory Fc receptors. In vitro, chemically linked bispecific antibodies directed against the Fc gamma receptors Fc gamma RIII (CD16) and Fc gamma RI (CD64), and the Fc alpha receptor Fc alpha RI (CD89), were significantly more effective than conventional IgG antibodies. Recent animal studies confirmed the therapeutic potential of these constructs. However, results from clinical trials have been less promising so far and have revealed clear limitations of these molecules, such as short plasma half-lives compared with conventional antibodies. In this review, we briefly summarize the scientific background for bispecific antibodies, and describe the rationale for the generation of novel recombinant molecules. These constructs may allow us to more specifically tailor pharmacokinetic properties to the demands of clinical applications." @default.
- W2068482302 created "2016-06-24" @default.
- W2068482302 creator A5012207265 @default.
- W2068482302 creator A5068320500 @default.
- W2068482302 date "2002-08-01" @default.
- W2068482302 modified "2023-10-15" @default.
- W2068482302 title "Bispecific antibodies targeting cancer cells" @default.
- W2068482302 doi "https://doi.org/10.1042/bst0300507" @default.
- W2068482302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12196124" @default.
- W2068482302 hasPublicationYear "2002" @default.
- W2068482302 type Work @default.
- W2068482302 sameAs 2068482302 @default.
- W2068482302 citedByCount "56" @default.
- W2068482302 countsByYear W20684823022012 @default.
- W2068482302 countsByYear W20684823022013 @default.
- W2068482302 countsByYear W20684823022014 @default.
- W2068482302 countsByYear W20684823022015 @default.
- W2068482302 countsByYear W20684823022016 @default.
- W2068482302 countsByYear W20684823022017 @default.
- W2068482302 countsByYear W20684823022018 @default.
- W2068482302 countsByYear W20684823022021 @default.
- W2068482302 countsByYear W20684823022022 @default.
- W2068482302 crossrefType "journal-article" @default.
- W2068482302 hasAuthorship W2068482302A5012207265 @default.
- W2068482302 hasAuthorship W2068482302A5068320500 @default.
- W2068482302 hasConcept C114684123 @default.
- W2068482302 hasConcept C147483822 @default.
- W2068482302 hasConcept C154317977 @default.
- W2068482302 hasConcept C159654299 @default.
- W2068482302 hasConcept C167672396 @default.
- W2068482302 hasConcept C170493617 @default.
- W2068482302 hasConcept C202751555 @default.
- W2068482302 hasConcept C203014093 @default.
- W2068482302 hasConcept C2776447464 @default.
- W2068482302 hasConcept C2779931124 @default.
- W2068482302 hasConcept C2781462264 @default.
- W2068482302 hasConcept C3020495827 @default.
- W2068482302 hasConcept C45121317 @default.
- W2068482302 hasConcept C502942594 @default.
- W2068482302 hasConcept C51785407 @default.
- W2068482302 hasConcept C542903549 @default.
- W2068482302 hasConcept C55493867 @default.
- W2068482302 hasConcept C86803240 @default.
- W2068482302 hasConcept C8891405 @default.
- W2068482302 hasConceptScore W2068482302C114684123 @default.
- W2068482302 hasConceptScore W2068482302C147483822 @default.
- W2068482302 hasConceptScore W2068482302C154317977 @default.
- W2068482302 hasConceptScore W2068482302C159654299 @default.
- W2068482302 hasConceptScore W2068482302C167672396 @default.
- W2068482302 hasConceptScore W2068482302C170493617 @default.
- W2068482302 hasConceptScore W2068482302C202751555 @default.
- W2068482302 hasConceptScore W2068482302C203014093 @default.
- W2068482302 hasConceptScore W2068482302C2776447464 @default.
- W2068482302 hasConceptScore W2068482302C2779931124 @default.
- W2068482302 hasConceptScore W2068482302C2781462264 @default.
- W2068482302 hasConceptScore W2068482302C3020495827 @default.
- W2068482302 hasConceptScore W2068482302C45121317 @default.
- W2068482302 hasConceptScore W2068482302C502942594 @default.
- W2068482302 hasConceptScore W2068482302C51785407 @default.
- W2068482302 hasConceptScore W2068482302C542903549 @default.
- W2068482302 hasConceptScore W2068482302C55493867 @default.
- W2068482302 hasConceptScore W2068482302C86803240 @default.
- W2068482302 hasConceptScore W2068482302C8891405 @default.
- W2068482302 hasIssue "4" @default.
- W2068482302 hasLocation W20684823021 @default.
- W2068482302 hasLocation W20684823022 @default.
- W2068482302 hasOpenAccess W2068482302 @default.
- W2068482302 hasPrimaryLocation W20684823021 @default.
- W2068482302 hasRelatedWork W1608327333 @default.
- W2068482302 hasRelatedWork W1660604212 @default.
- W2068482302 hasRelatedWork W2003286718 @default.
- W2068482302 hasRelatedWork W2038922639 @default.
- W2068482302 hasRelatedWork W2170516337 @default.
- W2068482302 hasRelatedWork W27456578 @default.
- W2068482302 hasRelatedWork W2943776820 @default.
- W2068482302 hasRelatedWork W4238744887 @default.
- W2068482302 hasRelatedWork W4362551478 @default.
- W2068482302 hasRelatedWork W4362628324 @default.
- W2068482302 hasVolume "30" @default.
- W2068482302 isParatext "false" @default.
- W2068482302 isRetracted "false" @default.
- W2068482302 magId "2068482302" @default.
- W2068482302 workType "article" @default.